Imatinib Sandoz (Imatinib)

Imatinib is a targeted tyrosine‑kinase inhibitor used in hematologic and solid‑tumor malignancies driven by specific genetic abnormalities, providing disease control and prolonging survival.

• Chronic myeloid leukemia (CML): reduces leukemic cell proliferation, achieves durable molecular remission, and can enable long‑term disease control.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): improves remission rates and overall survival when combined with standard chemotherapy regimens.
• Gastrointestinal stromal tumor (GIST): inhibits tumor growth in patients with activating KIT or PDGFRA mutations, leading to disease stabilization and symptom relief.

• Imatinib selectively binds to the ATP‑binding pocket of BCR‑ABL tyrosine kinase as well as related kinases such as c‑KIT and platelet‑derived growth factor receptor (PDGFR). By blocking ATP access, it prevents phosphorylation of downstream signaling proteins, thereby inhibiting proliferative and survival pathways in malignant cells that depend on these kinases. The inhibition is competitive and reversible, leading to cell‑cycle arrest and apoptosis in sensitive tumor populations.

Imatinib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Diarrhea: loose stools, often transient.
• Fatigue: general tiredness.
• Edema: swelling of extremities.
• Muscle cramps: occasional tightness.
• Rash: mild skin irritation.

Serious or Rare Side Effects

• Hepatotoxicity: elevated liver enzymes or liver injury.
• Myelosuppression: neutropenia, anemia, or thrombocytopenia.
• Cardiotoxicity: heart failure or reduced left‑ventricular function.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing Imatinib, clinicians should consider several precautionary measures to ensure patient safety.

• Monitor blood counts: perform regular CBC to detect myelosuppression.
• Assess liver function: check hepatic enzymes before and during therapy.
• Evaluate cardiac status: baseline and periodic echocardiograms for patients with risk factors.
• Avoid in severe infection: postpone treatment if active serious infection is present.
• Counsel on drug interactions: review concomitant medications that affect CYP3A4 metabolism.
• Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture.

Imatinib interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce Imatinib exposure.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase risk of toxicity.
• Macrolide antibiotics (e.g., erythromycin): can increase Imatinib concentrations and toxicity.

Moderate Interactions (Monitor Closely)

• Acid‑reducing agents (e.g., proton pump inhibitors, antacids): may lower absorption.
• Antifungal azoles (e.g., fluconazole): modestly raise Imatinib levels.
• Concomitant chemotherapy (e.g., cytarabine): potential additive myelosuppression.
• Warfarin: may require INR monitoring due to altered anticoagulant effect.